Evidence map›Paper›PMID 27994550›Full record

ArticleFrontiers in pharmacology2016

Anti-Proliferative and Apoptosis-Inducing Effect of Theabrownin against Non-small Cell Lung Adenocarcinoma A549 Cells.

Feifei Wu, Li Zhou, Wangdong Jin, Weiji Yang, Ying Wang, Bo Yan, Wenlin Du, Qiang Zhang, Lei Zhang, Yonghua Guo and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Feifei WuInstitute for Cell-Based Drug Development of Zhejiang Province, S-Evans Biosciences, Ltd. Hangzhou, China.
Li ZhouInstitute of Orthopaedics and Traumatology, Zhejiang Chinese Medical University Hangzhou, China.
Wangdong JinInstitute of Orthopaedics and Traumatology, Zhejiang Chinese Medical University Hangzhou, China.
Weiji YangInstitute of Orthopaedics and Traumatology, Zhejiang Chinese Medical University Hangzhou, China.
Ying WangInstitute of Orthopaedics and Traumatology, Zhejiang Chinese Medical University Hangzhou, China.
Bo YanInstitute of Orthopaedics and Traumatology, Zhejiang Chinese Medical University Hangzhou, China.
Wenlin DuInstitute for Cell-Based Drug Development of Zhejiang Province, S-Evans Biosciences, Ltd. Hangzhou, China.
Qiang ZhangInstitute for Cell-Based Drug Development of Zhejiang Province, S-Evans Biosciences, Ltd. Hangzhou, China.
Lei ZhangSchool of Medicine, Zhejiang University Hangzhou, China.
Yonghua GuoInstitute for Cell-Based Drug Development of Zhejiang Province, S-Evans Biosciences, Ltd. Hangzhou, China.
Jin ZhangTheabio Co., Ltd Hangzhou, China.
Letian ShanInstitute of Orthopaedics and Traumatology, Zhejiang Chinese Medical University Hangzhou, China.
Thomas EfferthDepartment of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz, Germany.
Zhejiang Chinese Medical University · CNJohannes Gutenberg University Mainz · DEZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the highest cancer incidence rate, lung cancer, especially non-small cell lung cancer (NSCLC), is the leading cause of cancer death in the world. Tea (leaves of

Indexed as

A549 cellsapoptosislung cancerP53theabrownin

Identifiers

PMID27994550
PMCPMC5133245
OpenAlexW2560577615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.